Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase: the DASPERSE study
Chronic, low-grade adverse events are common in patients with chronic myeloid leukemia who are treated with imatinib. These events may decrease patient quality of life and adherence, and may ultimately contribute to a suboptimal response. Alternative, second-generation tyrosine kinase inhibitors, su...
Gespeichert in:
| Hauptverfasser: | , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
20 March 2018
|
| In: |
Annals of hematology
Year: 2018, Jahrgang: 97, Heft: 8, Pages: 1357-1367 |
| ISSN: | 1432-0584 |
| DOI: | 10.1007/s00277-018-3295-8 |
| Online-Zugang: | Resolving-System, Volltext: https://doi.org/10.1007/s00277-018-3295-8 Verlag: https://link.springer.com/article/10.1007%2Fs00277-018-3295-8 
|
| Verfasserangaben: | Dong-Wook Kim, Susanne Saussele, Loretta A. Williams, Hesham Mohamed, Yuanxin Rong, Teresa Zyczynski, Javier Pinilla-Ibarz, Elisabetta Abruzzese |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1679109596 | ||
| 003 | DE-627 | ||
| 005 | 20220817003341.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 191018s2018 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00277-018-3295-8 |2 doi | |
| 035 | |a (DE-627)1679109596 | ||
| 035 | |a (DE-599)KXP1679109596 | ||
| 035 | |a (OCoLC)1341248081 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Kim, Dong Wook |e VerfasserIn |0 (DE-588)1181019745 |0 (DE-627)1662636938 |4 aut | |
| 245 | 1 | 0 | |a Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase |b the DASPERSE study |c Dong-Wook Kim, Susanne Saussele, Loretta A. Williams, Hesham Mohamed, Yuanxin Rong, Teresa Zyczynski, Javier Pinilla-Ibarz, Elisabetta Abruzzese |
| 264 | 1 | |c 20 March 2018 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 18.10.2019 | ||
| 520 | |a Chronic, low-grade adverse events are common in patients with chronic myeloid leukemia who are treated with imatinib. These events may decrease patient quality of life and adherence, and may ultimately contribute to a suboptimal response. Alternative, second-generation tyrosine kinase inhibitors, such as dasatinib, are available with the potential to reduce adverse events, improve tolerability, and support long-term treatment goals. We present the final, primary analysis of DASPERSE/CA180-400 (NCT01660906), an open-label, multicenter, phase IV study designed to determine whether chronic, low-grade nonhematologic adverse events in imatinib-treated patients improve after switching to dasatinib, without affecting efficacy. | ||
| 650 | 4 | |a Adverse effects | |
| 650 | 4 | |a Chronic myeloid leukemia | |
| 650 | 4 | |a Quality of life | |
| 650 | 4 | |a Tyrosine kinase | |
| 700 | 1 | |a Saußele, Susanne |d 1968- |e VerfasserIn |0 (DE-588)115839860 |0 (DE-627)69162786X |0 (DE-576)29010694X |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Annals of hematology |d Berlin : Springer, 1991 |g 97(2018), 8, Seite 1357-1367 |h Online-Ressource |w (DE-627)253389852 |w (DE-600)1458429-3 |w (DE-576)072283157 |x 1432-0584 |7 nnas |a Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase the DASPERSE study |
| 773 | 1 | 8 | |g volume:97 |g year:2018 |g number:8 |g pages:1357-1367 |g extent:11 |a Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase the DASPERSE study |
| 856 | 4 | 0 | |u https://doi.org/10.1007/s00277-018-3295-8 |x Resolving-System |x Verlag |3 Volltext |
| 856 | 4 | 0 | |u https://link.springer.com/article/10.1007%2Fs00277-018-3295-8 |x Verlag |
| 951 | |a AR | ||
| 992 | |a 20191018 | ||
| 993 | |a Article | ||
| 994 | |a 2018 | ||
| 998 | |g 115839860 |a Saußele, Susanne |m 115839860:Saußele, Susanne |d 60000 |d 61200 |e 60000PS115839860 |e 61200PS115839860 |k 0/60000/ |k 1/60000/61200/ |p 2 | ||
| 999 | |a KXP-PPN1679109596 |e 3524301533 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"physDesc":[{"extent":"11 S."}],"relHost":[{"id":{"issn":["1432-0584"],"eki":["253389852"],"zdb":["1458429-3"]},"origin":[{"publisherPlace":"Berlin ; Heidelberg ; New York","publisher":"Springer","dateIssuedKey":"1991","dateIssuedDisp":"1991-"}],"physDesc":[{"extent":"Online-Ressource"}],"title":[{"title":"Annals of hematology","subtitle":"organ of: Gesellschaft für Thrombose- und Hämostaseforschung, DGHO, Deutsche Gesellschaft für Hämatologie und Onkologie e.V., ÖGHO, Österreichische Gesellschaft für Hämatologie und Onkologie","title_sort":"Annals of hematology"}],"part":{"text":"97(2018), 8, Seite 1357-1367","volume":"97","extent":"11","year":"2018","pages":"1357-1367","issue":"8"},"titleAlt":[{"title":"Hematology"}],"pubHistory":["62, 1 (Februrary 1991)-"],"language":["eng"],"recId":"253389852","disp":"Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase the DASPERSE studyAnnals of hematology","type":{"media":"Online-Ressource","bibl":"periodical"},"note":["Gesehen am 24.04.2025","Fortsetzung der Druck-Ausgabe","Ungezählte Beil. ab 80.2001: Supplement"]}],"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"20 March 2018"}],"id":{"eki":["1679109596"],"doi":["10.1007/s00277-018-3295-8"]},"name":{"displayForm":["Dong-Wook Kim, Susanne Saussele, Loretta A. Williams, Hesham Mohamed, Yuanxin Rong, Teresa Zyczynski, Javier Pinilla-Ibarz, Elisabetta Abruzzese"]},"type":{"media":"Online-Ressource","bibl":"article-journal"},"note":["Gesehen am 18.10.2019"],"language":["eng"],"recId":"1679109596","title":[{"subtitle":"the DASPERSE study","title":"Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase","title_sort":"Outcomes of switching to dasatinib after imatinib-related low-grade adverse events in patients with chronic myeloid leukemia in chronic phase"}],"person":[{"family":"Kim","given":"Dong Wook","display":"Kim, Dong Wook","roleDisplay":"VerfasserIn","role":"aut"},{"family":"Saußele","given":"Susanne","roleDisplay":"VerfasserIn","display":"Saußele, Susanne","role":"aut"}]} | ||
| SRT | |a KIMDONGWOOOUTCOMESOF2020 | ||